What changed for Hepatitis B
A plain English summary of what recently moved in the public data Voxsanity tracks for Hepatitis B. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 119 to 124 (+5)
- Trials on record 1,661 to 1,695 (+34)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Hepatitis B in July 2026. Voxsanity tracks 3 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 137 trials tracked for Hepatitis B that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04749368 · results posted 23 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04749368) looked at a treatment approach for chronic hepatitis B (a long-term liver infection). Participants were divided into three groups: Cohort A (11 people), Cohort B (39 people), and Cohort C (41 people), giving a total of 91 participants. The trial was measuring whether participants could clear a specific protein linked to the hepatitis B virus (called HBsAg) from their blood after stopping a type of antiviral tablet, and it also tracked unwanted health events that occurred during the study. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06422767 · results posted 10 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06422767) enrolled 46 participants in total. They were divided into four groups: 5 people received four doses of bepirovirsen (an injectable medicine being studied for hepatitis B) under the skin, 5 received four dummy (placebo) injections, 18 received three doses of bepirovirsen, and 18 received three placebo injections. All 46 participants completed the study. The main thing the trial was measuring was whether bepirovirsen — given at higher-than-usual doses — affected the heart's electrical activity, specifically a measu...
-
NCT04980482 · results posted 29 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04980482) enrolled 43 participants in an initial "lead-in" phase, who were then divided into four smaller groups (called Cohorts A1, A2, B1, and B2, with 12, 13, 8, and 10 participants respectively) for the main treatment phase. The trial was investigating a combination of an experimental medicine called AB-729 and another medicine called Peg-IFNα-2a in people with hepatitis B. The main thing the trial set out to measure was how often and how seriously participants experienced unwanted health events (called "treatment-emer...
-
NCT04412863 · results posted 16 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04412863) enrolled 84 adults with chronic hepatitis B across six groups. Each group received a different combination or duration of two investigational treatments — a drug called VIR-2218 and/or a medicine called PEG-IFNα — while also continuing on standard background antiviral tablets (NRTIs). The groups ranged in size from 5 to 18 participants. The trial was primarily measuring how many people in each group experienced side effects or abnormal test results during treatment. The reported data shows that adverse events (u...
-
NCT05763576 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05763576) involved 60 people across nine groups. Twelve participants received a placebo, and the remaining 48 received varying doses of the study drug, RO7565020. The trial was split into two parts: Part 1a tested the drug in healthy volunteers across six groups (some receiving the drug by injection under the skin, others directly into the vein), and Part 2a tested it in people living with chronic hepatitis B (a long-term liver infection) across two groups. The trial was primarily measuring how many participants experience...
-
NCT05612581 · results posted 26 November 2025
According to the results reported on ClinicalTrials.gov, this trial (which ran two related studies called STRIVE and THRIVE) looked at an experimental treatment approach for chronic hepatitis B — a viral liver infection. The trial tested combinations of investigational drugs (VIR-3434, VIR-2218, and/or PEG-IFNα) alongside an existing antiviral medicine called TDF (tenofovir disoproxil fumarate). The trial was organised into several groups, but based on the submitted data, only two groups had participants recorded: one group in the THRIVE study (Cohort 4a, testing VIR-3434 + VIR-2218 + TDF) wit...
-
NCT04297917 · results posted 12 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04297917) enrolled 47 participants across six groups. Five healthy volunteers received a low dose of the vaccine, five received a high dose, six people living with chronic hepatitis B received a low dose, and five received a high dose. Additionally, 15 healthy volunteers who had previously received the AstraZeneca (AZD1222) COVID-19 vaccine and 11 who had previously received a Pfizer or Moderna COVID-19 vaccine each received the high dose. The trial was primarily measuring reactions and unwanted events following vaccinatio...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04891770 · results posted 24 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04891770) enrolled 103 people with chronic hepatitis B infection across three groups. Cohort 1 (42 people) received four treatments together: TAF, VIR-2218, selgantolimod (SLGN), and nivolumab. Cohort 2 Group A (40 people) received VIR-2218, SLGN, and nivolumab. Cohort 2 Group B (21 people) received SLGN and nivolumab only. The trial's main goal was to measure how many participants achieved what researchers called a "functional cure" — defined as losing a specific hepatitis B protein from the blood (called HBsAg) while als...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02476695 · results posted 5 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 412 people with chronic hepatitis B. The study was measuring how well a non-invasive scanning device called FibroTouch could detect different stages of liver scarring (known as fibrosis), compared to a liver tissue sample (biopsy), which was used as the reference standard. Of the 412 participants, 11 had no fibrosis (F0), 162 had stage F1, 118 had stage F2, 95 had stage F3, and 26 had the most advanced stage (F4). All 412 participants completed the study. The reported data shows how accurately the FibroTouch device's...
-
NCT04544956 · results posted 19 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 12 participants, all of whom received a 300 mg dose of the investigational drug GSK3228836 (also known as bepirovirsen). Eleven of the 12 participants completed the study, while one did not. The trial was measuring changes in blood markers related to hepatitis B — specifically a protein called HBsAg (hepatitis B surface antigen) and the virus's genetic material (HBV DNA). The aim was to see how many participants reached levels of these markers that were too low to be detected by the tests used, which researchers descr...
-
NCT04398706 · results posted 12 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04398706) tested three experimental pneumococcal vaccines — called SP0202-IIb, SP0202-VI, and SP0202-VII — and compared them to an already-approved vaccine called Prevnar 13. The trial ran in two stages: a smaller Stage I with 35 children in each of the four groups (140 in total), and a larger Stage II with roughly 176–179 children per group (712 in total). Across both stages, the trial enrolled 852 participants in all. The study was primarily focused on tracking various types of reactions and health events that occurred a...
-
NCT04535544 · results posted 6 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04535544) looked at a treatment called JNJ-73763989 combined with a standard hepatitis B antiviral medicine (called a nucleos(t)ide analogue, or NA) in people with chronic hepatitis D virus (HDV) infection. The trial was run in two parts. Part 1 enrolled 22 participants (17 receiving JNJ-73763989 plus NA, and 5 receiving a placebo plus NA). Part 2 enrolled 30 participants (24 receiving JNJ-73763989 plus NA, and 6 receiving placebo plus NA). The trial included a double-blind phase (up to about one year, where neither doctor...
-
NCT02952924 · results posted 31 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02952924) tested an investigational drug called RO7049389 and enrolled a total of 187 participants across multiple groups. The study was divided into several parts: some participants received single doses of the drug (to see how the body handles it after one dose), some received multiple doses over time, and others took part in proof-of-mechanism and additional cohort stages. A number of participants in each group received a placebo (a dummy treatment with no active ingredient) for comparison. The vast majority of particip...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04423393 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04423393) tested a drug called VIR-3434 across four parts (Parts A–D), involving a total of 113 participants. Part A included healthy volunteers who received different doses of VIR-3434 either as an injection under the skin (subcutaneous, or SC) or directly into a vein (intravenous, or IV), or a placebo (a dummy treatment with no active ingredient). Parts B, C, and D included people living with hepatitis B virus (HBV) who also received varying doses by injection or placebo. The trial was measuring how often participants ex...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04778904 · results posted 13 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04778904) enrolled 55 people with chronic hepatitis B infection across four groups. Group 1 (10 people) received a vaccine called MVA-HBV on its own. Group 2 (18 people) received a combination of two vaccines, ChAdOx1-HBV followed by MVA-HBV. Group 3 (18 people) received the same two-vaccine combination plus a drug called nivolumab. Group 4 (9 people) received both vaccines together with nivolumab given alongside each one. The trial was primarily measuring how often participants experienced adverse events (unwanted health...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03934736 · results posted 9 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03934736) enrolled 119 people who received a hepatitis B vaccine called HEPLISAV-B. Of those, 86 completed the trial and 33 did not. The trial was measuring two main things: how many participants developed a protective level of antibodies against hepatitis B (a sign that the immune system had responded to the vaccine), and how many experienced certain types of adverse events (unwanted health effects), including those serious enough to require a doctor's visit or hospitalisation. The reported data shows that, by the end of...
-
NCT04456504 · results posted 3 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 49 healthcare workers who had previously not responded to five or more doses of the standard hepatitis B vaccine (the type that uses an aluminium adjuvant — a substance added to vaccines to boost the body's reaction). The trial was measuring whether these same people would produce a measurable immune response — specifically, a blood antibody level above a set threshold — after receiving a different hepatitis B vaccine that uses a different booster ingredient called CpG adjuvant, given as a two-dose course. The report...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03365947 · results posted 4 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03365947) tested an investigational treatment called ARO-HBV (also known as JNJ-3989) for chronic hepatitis B virus infection. A total of 120 people took part across 19 different groups, receiving either varying doses of ARO-HBV — given at different dosing intervals and in some cases combined with another investigational medicine — or a placebo (an inactive treatment used for comparison). The trial was primarily measuring how many participants experienced unwanted medical events that were thought to be possibly or probably...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04535037 · results posted 27 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04535037) enrolled 500 infants — 249 in the Infanrix Hexa group and 251 in the Vaxelis group. The trial was measuring the levels of a specific antibody (called anti-PRP) in children's blood at around 11 months of age, after they had received a booster dose of one of these two combination childhood vaccines. Anti-PRP is an antibody that the body makes in response to the Haemophilus influenzae type b (Hib) component of these vaccines. The study tracked how high antibody levels rose and what proportion of children reached cer...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02956850 · results posted 8 February 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02956850) enrolled a total of 170 participants across two main parts. Part 1 involved healthy volunteers who received either a single dose or multiple doses of the study drug RO7020531 (or a placebo), tested across several dose levels. Part 2 involved people living with chronic hepatitis B, again receiving either the study drug or a placebo across different dosing groups. All but one participant completed the trial. The trial was measuring how often participants experienced any adverse events (that is, any unwanted medical...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04820686 · results posted 14 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04820686) enrolled 65 people with hepatitis B across three treatment groups: 32 people received a combination of three treatments (vebicorvir, known as VBR, plus AB-729, plus a standard antiviral medicine); 16 people received VBR plus the standard antiviral; and 17 people received AB-729 plus the standard antiviral. The trial was measuring how these different drug combinations behaved in participants, including how many people experienced unwanted health events, abnormal lab results, or had to stop treatment early. Only 2...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04781647 · results posted 6 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04781647) enrolled 54 people with hepatitis B, split across three treatment groups: 20 people received ABI-H0731 combined with entecavir (a standard antiviral tablet); 17 received ABI-H0731 with entecavir plus pegylated-interferon alpha (an immune-stimulating injection); and 17 received entecavir plus pegylated-interferon alpha only. The trial was primarily measuring how many participants experienced unwanted health events (called adverse events), unusual laboratory test results, or stopped treatment early. It also tracked...
-
NCT04449029 · results posted 16 May 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04449029) enrolled 457 adults with chronic hepatitis B — a long-term liver infection. Participants were split into eight groups based on two things: whether they were already taking a standard antiviral medicine called nucleoside/nucleotide analogue (NA) therapy, and which dosing schedule of the investigational drug GSK3228836 (also known as bepirovirsen) they received — either 24 weeks of the study drug, two different 12-week schedules, or starting with placebo for 12 weeks then switching to the study drug. The trial's ma...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04454567 · results posted 20 October 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04454567) enrolled just two people — one person received a combination of the investigational drug ABI-H0731 plus a standard antiviral treatment (referred to as SOC NrtI), and one person received a placebo plus the same standard antiviral treatment. The trial was set up to measure things like unwanted health events (adverse events), unexpected changes in lab test results, early stopping of treatment, and whether a hepatitis B virus measurement in the blood (called HBV DNA) fell below a detectable threshold by Week 48. Neit...
-
NCT04465916 · results posted 12 October 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04465916) enrolled 26 people in total — 19 in the experimental arm (receiving vonafexor on top of their existing hepatitis B treatment) and 7 in the control arm (receiving their existing treatment alone). All 19 people in the experimental arm completed the study, while 6 out of 7 in the control arm completed it. The trial was primarily measuring changes in a protein called HBsAg (hepatitis B surface antigen — a marker found in the blood of people with hepatitis B infection), looking at how much its level changed over 16 we...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04398134 · results posted 26 August 2022
According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called ABI-H2158 combined with an existing hepatitis B medicine called entecavir (ETV), compared with a placebo (inactive treatment) plus entecavir, in people living with chronic hepatitis B. Participants were divided into two groups based on a marker of the virus called HBeAg — those who tested positive for it and those who tested negative. In total, 88 people started the trial: 32 in the HBeAg-positive group receiving ABI-H2158 plus entecavir, 11 in the HBeAg-positive placebo group, 33 in the HBeAg-nega...
-
NCT03434353 · results posted 4 April 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03434353) enrolled 123 people across five groups to study a drug called inarigivir soproxil in people with hepatitis B. Four of the groups received inarigivir soproxil at different doses (50 mg, 100 mg, 200 mg, or 400 mg) combined with another antiviral medication, while one group received an antiviral medication alone as a comparison. The trial was mainly measuring changes in a hepatitis B surface protein (called HBsAg) in participants' blood — a marker used to track the virus — after 12 weeks of treatment. Not all partic...
-
NCT03685708 · results posted 15 December 2021
According to the results reported on ClinicalTrials.gov, this trial looked at how well a hepatitis B vaccine called HEPLISAV-B produced a protective level of immunity in people with a blood cancer called chronic lymphocytic leukaemia (CLL). A total of 78 people started the study across three groups: 14 were receiving a treatment called acalabrutinib, 18 were receiving a treatment called ibrutinib (both are a type of targeted cancer medicine), and 46 had not yet started any CLL treatment. The vaccine was given in two doses over six months, and the main thing being measured was how many particip...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03672188 · results posted 13 December 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03672188) tested a drug called VIR-2218 across three parts (A, B, and C). Part A gave participants a single dose of VIR-2218 (at doses ranging from 50 mg to 900 mg) or a placebo. Parts B and C gave participants multiple doses over time (ranging from 20 mg to 200 mg) or a placebo. In total, 86 people started the trial across all groups. The trial was primarily measuring how many participants experienced adverse events (unexpected health changes or symptoms) and whether there were any notable abnormalities in things like blo...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03410953 · results posted 8 July 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 67 adults who received a hepatitis B vaccine called Fendrix. All 67 participants completed the study — none dropped out. The trial was measuring how many people developed what researchers considered a "protective level" of antibodies (proteins the immune system makes in response to a vaccine) after receiving the treatment. The reported data shows that the primary outcome — the number of participants who reached the targeted antibody level — was measured at multiple points: after each dose of the vaccine. The results...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 137 reported results for Hepatitis B
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, hepatitis B currently attracts a very large amount of public research funding from the United States government, and the direction of that funding has remained broadly steady from year to year. For patients, this signals that hepatitis B is an established research priority rather than a newly emerging area of interest. A stable and substantial funding base generally...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.